BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Polyplus Transfection Announces the Appointment of Ten Additional Biologists and Chemists to Support Multiple Pre-Clinical Studies


9/15/2011 12:47:49 PM

Strasbourg, France, September 15, 2011 - Polyplus-transfection SA, which specializes in the development of innovative solutions for the delivery of nucleic acids in research and therapeutics, today celebrates ten years of continuous growth.

From its launch in 2001, Polyplus-transfection has sold its lines of proprietary transfection reagents through a large network of international distributors covering more than 30 countries worldwide. During the past decade, Polyplus-transfection has evolved into two business units; the core commercial transfection reagent business and therapeutic research business focused on nucleic acid delivery systems, and has moved from four to forty two employees. In partnership with its private equity investors, Polyplus has part funded its therapeutic research with revenue from its commercial transfection reagent sales, funding and loans, and has successfully raised a total of EUR 7.8M in venture funding since 2001.

The most recent funding round of EUR 2.5M which closed in December 2010, is driving the acceleration of Polyplus’ pre-clinical study programs with the hire of ten additional scientists and the expansion of Polyplus’ laboratory and office facilities in Illkirch (France). Polyplus-transfection is a specialist of in-vivo intracellular nucleic acid transfer, and is currently conducting two main research programs dedicated to development of RNA interference-based therapeutics: STICKY SIRNA and RNAPLUS. Since 2001, the scientific team of the company has authored more than 20 scientific papers and has significantly expanded the companies IP estate in the field of nucleic acid delivery.

“Ten years is a significant milestone for any company. Polyplus-transfection has clearly proven the sustainability of its business model and now serves thousands of customers worldwide with quality products, while continuing to invest in the build out of a world class research and discovery organisation,” says Mark Bloomfield, CEO of Polyplus-transfection. “Moreover, Polyplus continues to benefit from a close and valued relationship with its institutional investors who have provided the funding, support and guidance needs to bring our STICKY SIRNA and SIRNAPLUS delivery technologies into pre-clinical development.”

“The latest results from our preclinical studies in lung metastatic cancer and prostate cancer models show that STICKY SIRNA is effective in inhibiting both the cell cycle as well as chemotherapy resistance resulting in significantly reduced tumor growth and increase mice survival when administered in combination with widely used chemotherapy drugs such as Cisplatin,” says Dr. Patrick Erbacher CSO at Polyplus-transfection. “Further, based on this preclinical data we are now seeking partners to take STICKY SIRNA in to clinical trials as a powerful tool for antitumor therapy.”

About Polyplus-transfection

Polyplus-transfection SA is a biotechnology company that develops, markets and sells innovative solutions for the in vivo, in vitro and ex vivo delivery of nucleic acids in research, bioproduction and therapeutics. Located close to the University of Strasbourg in Eastern France, Polyplus-transfection has been ISO 9001-certified since 2002 and supplies its proprietary range of reagents for the transfection of genes, oligonucleotides and siRNA through a worldwide distributor network. Polyplus reagents are involved in a growing number of clinical trials worldwide. In addition, Polyplus-transfection holds a broad estate of patents and licenses including original methods for therapeutic siRNA delivery.

For more information, please visit the Polyplus-transfection web site at:

Mark Tidmarsh

ANDREW LLOYD & ASSOCIATES

http://www.ala.com

mark@ala.com

Brighton Business Centre 95 Ditchling Road Brighton BN1 4ST ENGLAND

Tel: +44 1273 675100

Fax: +44 1273 675400

55 rue Boissonade 75014 Paris FRANCE

Tel: +33 1 56 54 07 00

Fax: +33 1 56 54 07 01

INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATION

Mark Tidmarsh

ANDREW LLOYD & ASSOCIATES

http://www.ala.com

mark@ala.com

Brighton Business Centre 95 Ditchling Road Brighton BN1 4ST ENGLAND

Tel: +44 1273 675100

Fax: +44 1273 675400

55 rue Boissonade 75014 Paris FRANCE

Tel: +33 1 56 54 07 00

Fax: +33 1 56 54 07 01

INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATION



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES